Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma ADR (NQ: ASND )

138.35 -2.75 (-1.95%)
Streaming Delayed Price Updated: 2:35 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma ADR

< Previous 1 2 3 4 5 6 Next >
The Latest Analyst Ratings for Ascendis Pharma
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
FDA Rejects Ascendis Pharma's TransCon PTH For Hypoparathyroidism
The FDA issued a complete response letter (CRL) for Ascendis Pharma A/S's 
Via Benzinga
Why Shares of Ascendis Pharma Are Climbing Monday
A critical response letter from the FDA means hope remains for the company's hyperthyroidism therapy candidate. 
Via The Motley Fool
US Stocks Rise; Norwegian Cruise Line Posts Q1 Results
U.S. stocks traded higher this morning, ahead of the Federal Reserve’s monetary policy meeting. Following the market opening Monday, the Dow traded up 0.15% to 34,147.97, while the NASDAQ inched up... 
Via Benzinga
IVERIC bio, Ascendis Pharma And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Apollomics, Inc. (NASDAQ: APLM) surged 58.4% to $7.35 in pre-market trading... 
Via Benzinga
Why Ascendis Pharma Stock Is Crashing This Week
The FDA put a roadblock in the path to market for Ascendis' hypoparathyroidism drug. 
Via The Motley Fool
Analyst Ratings for Ascendis Pharma
Via Benzinga
Why Ascendis Pharma Stock Is Plunging Today
A regulatory hiccup is weighing on the biopharma's shares today. 
Via The Motley Fool
Bragar Eagel & Squire, P.C. Is Investigating Fox, Ascendis, and Shift4 and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Hedge Funds Fall Short: Underperforming Low-Cost S&P 500 ETF By 6% In 2023. Here's Why.
So far, 2023 has not started well for the hedge fund sector, as a common SPDR S&P 500 Trust ETF (ARCA: SPY) fared much better than the Global X Guru Index ETF (ARCA: GURU), a fund that invests in the... 
Via Benzinga
NASDAQ: ASND Shareholder Notice: Investigation over Possible Securities Laws Violations by Ascendis Pharma A/S
San Diego, CA -- (SBWIRE) -- 04/17/2023 -- Ascendis Pharma A/S is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation - ASND
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Ascendis Pharma Flags Regulatory Delay In US For Its Hypoparathyroidism Candidate
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
ASCENDIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Ascendis Pharma A/S on Behalf of Ascendis Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2023
Via Benzinga
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ascendis Pharma A/S (ASND) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Nasdaq Down 80 Points; VirTra Shares Spike Higher
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dropping around 80 points on Monday. The Dow traded up 0.89% to 33,571.43 while the NASDAQ fell 0.66% to 12,142.07. The S&P... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Up Triple Digits As Second Quarter Kicks Off
The Dow Jones Industrial Average is up 146 points midday to kick off the second quarter, while the S&P 500 Index inches lower, and the Nasdaq Composite sits firmly in the red. 
Via Talk Markets
Why Heska Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Nogin, Inc. (NASDAQ: NOGN) shares surged 172.4% to $7.41. Guardforce AI Co., Limited (NASDAQ: GFAI) jumped 101% to $14.24 after climbing 50% on Friday. 
Via Benzinga
Crude Oil Jumps Over 6%; OncoSec Medical Shares Plummet
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite dropping more than 100 points on Monday. The Dow traded up 0.58% to 33,468.38 while the NASDAQ fell 0.96% to 12,104.67. The... 
Via Benzinga
Tesla, NIO And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mixed, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Ascendis Stock Plunges As FDA Identifies Deficiencies In Company's New Drug Application
The FDA decision prevents Ascendis from labeling and marketing the new drug application for TransCon PTH. ASND stock plunged 
Via Investor's Business Daily
ASND LOSS ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation – ASND
From The Rosen Law Firm, P.A.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.